KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $43.5 million.

  • Nektar Therapeutics' Operating Expenses fell 2566.66% to $43.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.7 million, marking a year-over-year decrease of 3473.07%. This contributed to the annual value of $203.6 million for FY2024, which is 4244.73% down from last year.
  • Nektar Therapeutics' Operating Expenses amounted to $43.5 million in Q3 2025, which was down 2566.66% from $47.4 million recorded in Q2 2025.
  • Nektar Therapeutics' Operating Expenses' 5-year high stood at $174.4 million during Q2 2022, with a 5-year trough of $14.8 million in Q4 2024.
  • In the last 5 years, Nektar Therapeutics' Operating Expenses had a median value of $73.3 million in 2024 and averaged $90.5 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 2590.39% in 2022, then tumbled by 7416.72% in 2024.
  • Nektar Therapeutics' Operating Expenses (Quarter) stood at $137.9 million in 2021, then crashed by 45.99% to $74.5 million in 2022, then dropped by 22.95% to $57.4 million in 2023, then tumbled by 74.17% to $14.8 million in 2024, then soared by 193.13% to $43.5 million in 2025.
  • Its last three reported values are $43.5 million in Q3 2025, $47.4 million for Q2 2025, and $55.0 million during Q1 2025.